Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 16/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.51 |
| ▸ | RXRB | P28702 | 9/20 | 0.50 |
| ▸ | RXRG | P48443 | 9/20 | 0.50 |
| ▸ | RARA | P10276 | 2/20 | 0.47 |
| ▸ | RARB | P10826 | 2/20 | 0.47 |
| ▸ | RARG | P13631 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6910205 | 0.86 | RXRA (1.00) | RXRACYP26A1RXRBRXRGRARA | |
| SCHEMBL8014653 | 0.85 | RXRA (0.55) | RXRACYP3A4CYP26A1RXRBRXRG | |
| SCHEMBL8016720 | 0.84 | CYP3A4 (0.56) | RXRACYP3A4CYP26A1RXRBRXRG | |
| SCHEMBL8016426 | 0.83 | RXRA (0.53) | RXRACYP3A4CYP26A1RXRBRXRG | |
| SCHEMBL8005377 | 0.82 | RXRA (0.74) | RXRACYP3A4CYP26A1RXRBRXRG | |
| SCHEMBL3982018 | 0.81 | RXRA (0.72) | RXRACYP3A4CYP26A1RXRBRXRG | |
| SCHEMBL2594347 | 0.78 | RXRA (0.73) | RXRACYP3A4CYP26A1RXRBRXRG | |
| SCHEMBL31758293 | 0.78 | RXRA (0.73) | RXRACYP3A4CYP26A1RXRBRXRG | |
| SCHEMBL8014342 | 0.78 | RXRA (0.50) | RXRACYP3A4CYP26A1RXRBRXRG | |
| SCHEMBL8165775 | 0.78 | RXRA (0.53) | RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040162354-A1 | Treatment of disease states which result from neoplastic cell proliferation using PPAR-gamma activators and compositions useful therefor | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2004-08-19 | — | — | US | disclosed |
| US-6646008-B1 | Administering peroxisome proliferator activated receptor(PPAR) and retinoid acid receptor agonists such as 6-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl) nicotinic acid, for prophylaxis of tumors | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2003-11-11 | — | — | US | disclosed |
| US-6586455-B1 | Administering retinoid and peroxisome proliferator-activated receptors to improve cell proliferation and differentiation of adipocytes; prophylaxis of cancer | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2003-07-01 | — | — | US | disclosed |
| US-6162815-A | RXR-agonist polycyclic aromatic compounds, pharmaceutical/cosmetic compositions comprising said compound and uses thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-12-19 | — | — | US | disclosed |
| US-6156788-A | Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-12-05 | — | — | US | disclosed |
| US-6015569-A | PYRIDINE OR PYRROLE DERIVATIVES OF POLYCYCLIC AROMATICS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2000-01-18 | — | — | US | disclosed |
| US-5766610-A | USEFUL FOR TREATMENT OF MAMMALIAN SKIN AND HAIR, RHEUMATISM, RESIPIRATORY SYSTEM DISORDER, CARDIOVASCULAR AND VISION DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-06-16 | — | — | US | disclosed |
| EP-0679630-B1 | Bicyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses | CIRD GALDERMA (FR) | 1998-05-06 | — | — | EP | disclosed |
| EP-0679630-A1 | Bicyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1995-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162354-A1 | Treatment of disease states which result from neoplastic cell proliferation using PPAR-gamma activators and compositions useful therefor | PPARA, PPARG, PPARD | RXRA 6/4885CYP3A4 1209/4885CYP26A1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.